Treatment of anaerobic infections with lincomycin and clindamycin.
about
Treatment of Bacteroides infection with clindamycin-2-phosphateIn vitro antimicrobial susceptibility of Actinobacillus actinomycetemcomitans.Clindamycin--efficacy and toxicity.Effect of clindamycin and lincomycin therapy on faecal flora.Chemotherapy of an experimental Fusobacterium (Sphaerophorus) necrophorum infection in mice.Rapid microassays for clindamycin and gentamicin when present together and the effect of pH and of each on the antibacterial activity of the other.Parenteral clindamycin phosphate: pharmacology with normal and abnormal liver function and effect on nasal staphylococciAntimicrobial susceptibilities of anaerobic bacteria: recent clinical isolates.Physical characterization of Bacteroides fragilis R plasmid pBF4.Anaerobic infection in cancer patients: comparative evaluation of clindamycin and cefoxitin.The penetration of metronidazole into synovial fluid.Susceptibility testing of anaerobic bacteriaThe prevention of surgical site infection in elective colon surgery.Septicemia and meningitis caused by Fusobacterium aquatile.Treatment of anaerobic bacterial infections with clindamycin-2-phosphate.Susceptibility of Clostridium ramosum to antimicrobial agents.Treatment of anaerobic infections with metronidazole.Anaerobic wound infections in cancer patients: comparative trial of clindamycin, tinidazole, and doxycyclinePediatric antimicrobial therapy I.Bacteroides bacteraemia. A clinical and bacteriological analysis of 51 patients.Antimicrobial in vitro susceptibility of actinomyces israelii and arachnia propionica.Antimicrobial therapy of anaerobic infections.Some clinical, immunological and bacteriological observations in a case of pyogenic arthritis due to bacteroides fragilis.Biochemical characterization and in vitro determination of antibiotic susceptibility of clinical isolates of Bacteroides fragilis.Clinical importance of infections due to Bacteroides fragilis and role of antibiotic therapy.
P2860
Q28363600-33E8815E-3205-475D-996D-D005E6E48C44Q33730756-44030E1B-D368-4FFC-B904-8557BB41CD5CQ33823463-CA27239F-E2F3-40C1-87DE-49BA45AAE647Q33846331-4C95F5B7-2BE5-43D4-820E-83B9555D1E97Q34910449-BECAFD03-977F-4D4A-81D5-70F00E2F87CBQ34911928-AC143C21-12F8-4093-809D-3F23D4E41CF4Q34916914-2E8D4013-DB04-4A5C-A1CB-1656721C1E97Q35656719-B1D249E6-0DF8-4E85-B30B-92528C52CFEFQ36321667-F0A78032-B286-4BA4-AFCF-E7B498BB20C9Q36483975-92C26674-F7C9-4B96-ABD5-DDF2EBD4C23CQ36716969-9E8C544C-64FE-4162-926B-E77A984B8057Q37151123-F64FB0BE-C564-49F3-B8AD-57A2639F849FQ37437094-55E0A211-70F1-4F3B-B53B-95C465C34129Q40162726-BC97C5AF-BF70-4E64-B7D5-68B1CF5277E6Q40943057-AD529B68-8D90-4A18-A294-E7A31CFB1CD2Q40943384-0FCD31C9-3659-48D0-94A5-BDA84E0F405EQ40944352-CF1A17E9-3665-48ED-975B-A3B6C5DEADBDQ40948378-A2C79153-108F-4224-A5CC-3B336D554A7EQ42417794-91259CF6-0E50-4219-845B-4D43431AE60BQ44047044-3FD60644-0B59-4CCC-BF01-62A8793E3BA4Q54394821-1CFFAA45-6201-4CE7-949D-EDA01D1C6675Q54623269-0383AC48-8BC8-476F-8F83-7A8289C8CBCDQ54630290-E36225DB-5303-40C5-BBF0-2C9C86DD4522Q54643598-EA895AE2-D7A8-43A4-BCAF-C4747CDC84A8Q55254391-75522B65-293A-4C89-81E9-F74B61B0B9C8
P2860
Treatment of anaerobic infections with lincomycin and clindamycin.
description
1972 nî lūn-bûn
@nan
1972年の論文
@ja
1972年学术文章
@wuu
1972年学术文章
@zh
1972年学术文章
@zh-cn
1972年学术文章
@zh-hans
1972年学术文章
@zh-my
1972年学术文章
@zh-sg
1972年學術文章
@yue
1972年學術文章
@zh-hant
name
Treatment of anaerobic infections with lincomycin and clindamycin.
@en
Treatment of anaerobic infections with lincomycin and clindamycin.
@nl
type
label
Treatment of anaerobic infections with lincomycin and clindamycin.
@en
Treatment of anaerobic infections with lincomycin and clindamycin.
@nl
prefLabel
Treatment of anaerobic infections with lincomycin and clindamycin.
@en
Treatment of anaerobic infections with lincomycin and clindamycin.
@nl
P2093
P1476
Treatment of anaerobic infections with lincomycin and clindamycin.
@en
P2093
Bartlett JG
Finegold SM
P304
P356
10.1056/NEJM197211162872002
P407
P577
1972-11-01T00:00:00Z